EMCURE1,966.40

Emcure Pharmaceuticals Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersMANKINDALKEMTORNTPHARMERISGRANULESCONCORDBIOINDGNCAPLIPOINTMcap ₹37,281 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations7,896.09,203.59,683.5
Other Income67.312.711.0
Total Income7,963.39,216.29,694.5
Expenses
+ Cost of Materials Consumed1,526.91,692.81,741.4
+ Purchases of Stock-in-Trade1,883.22,397.32,401.9
+ Changes in Inventories-263.5-433.0-215.1
+ Employee Benefit Expense1,446.31,552.21,568.2
+ Finance Costs175.8143.7148.5
+ Depreciation & Amortisation384.1415.0425.1
+ Other Expenses1,828.72,129.72,206.8
Total Expenses6,981.57,897.78,276.7
EBITDA1,474.41,864.51,980.3
EBIT1,090.31,449.51,555.2
Profit
PBT before Exceptional Items981.71,318.51,417.8
+ Exceptional Items-10.4-31.3-27.8
Pretax Income971.31,287.11,389.9
+ Current Tax292.2392.6421.8
+ Deferred Tax-28.3-46.7-50.8
Tax Expense263.9345.9370.9
Net Income707.5941.31,019.0
+ Net Income — Continuing Ops707.5941.31,019.0
+ Other Comprehensive Income31.5166.1107.2
Total Comprehensive Income739.01,107.41,126.2
Net Income to Common681.3924.41,011.4
Minority Interest26.116.97.6
Per Share
Basic EPS36.4348.7753.35
Diluted EPS36.4348.7753.35
Other Comprehensive Income — detail
+ Other Comprehensive Income31.5166.1107.2
+ Items NOT to be Reclassified to P&L-3.61.21.7
+ Tax on Items NOT to be Reclassified-1.00.30.5
+ Items to be Reclassified to P&L34.1165.3106.0
Comprehensive Income — Owners of Parent713.1166.1631.7
Comprehensive Income — Non-controlling Interests25.9-0.0-0.6
Per Share — as-filed variants
Basic EPS — Continuing Operations36.4348.7753.35
Diluted EPS — Continuing Operations36.4348.7753.35
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit4,749.45,546.55,755.2
Gross Margin %60.1560.2659.43
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)981.71,318.51,417.8
− Exceptional Items (reconciliation)-10.4-31.3-27.8
Net Income Adj (tax-effected)715.0964.21,039.4
EPS Adj36.8249.9654.42
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.0010.0010.00
Paid Up Equity Capital189.5189.6189.7
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.